ScholarIQanswers from OpenAlex
Cancer Institute (WIA)
InstitutionResearch output, impact & collaborations
Cancer Institute (WIA) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Cancer Institute (WIA)?
ScholarIQrecord summary
Cancer Institute (WIA) is a research organisation in Chennai, IN. OpenAlex records 18,577 works and 2,120,442 citations for it. 4,360 researchers list it as their most recent affiliation.
How many works does Cancer Institute (WIA) have?
ScholarIQindexed works
Cancer Institute (WIA) has 18,577 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Cancer Institute (WIA) have?
ScholarIQcitation count
Cancer Institute (WIA) has 2,120,442 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Cancer Institute (WIA)?
ScholarIQresearcher count
Cancer Institute (WIA) has 4,360 researchers in the ScholarIQ index.
What is the average h-index at Cancer Institute (WIA)?
ScholarIQavg h-index
Cancer Institute (WIA) has an average h-index of 67.8 in OpenAlex.
What is the ROR of Cancer Institute (WIA)?
ScholarIQror
The ROR for Cancer Institute (WIA) is on the source record.
What is the OpenAlex record for Cancer Institute (WIA)?
ScholarIQopenalex
The OpenAlex for Cancer Institute (WIA) is on the source record.
What is the Wikidata of Cancer Institute (WIA)?
ScholarIQwikidata
The Wikidata for Cancer Institute (WIA) is on the source record.
Who are the most-cited researchers behind Cancer Institute (WIA)?
ScholarIQtop researchers by citations
What are the most-cited papers on Cancer Institute (WIA)?
ScholarIQmost cited works
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
Emad El‐Omar, Mary Carrington, Wong-Ho Chow, Kenneth E.L. McColl, Jay H. Bream, Howard A. Young, Jesús Herrera, Jolanta Lissowska, Chiu-Chin Yuan, N. Rothman, George Lanyon, Maureen P. Martin, J F Fraumeni, Charles S. Rabkin
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T. Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent‐Puig, Frédérique Penault–Llorca, Philippe Rougier, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Federico Cappuzzo, Milo Frattini, Francesca Molinari, Piercarlo Saletti, Sara De Dosso, Miriam Martini, Alberto Bardelli, Salvatore Siena, Andrea Sartore‐Bianchi, Josep Tabernero, Teresa Macarulla, Frédéric FIORE, Alice Gangloff, Fortunato Ciardiello, Per Pfeiffer, Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar
Who collaborates most closely around Cancer Institute (WIA)?
ScholarIQco-authorship network
United States
100%
MOST FREQUENT PARTNER INSTITUTIONS
How much of the research on Cancer Institute (WIA) is open access?
ScholarIQopen access share
58%OPEN ACCESS